Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 8 5 W ELECTROLYTES versus TRAVASOL 4 25 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER.
AMINOSYN II 8.5% W/ELECTROLYTES vs TRAVASOL 4.25% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids serve as substrates for protein synthesis and provide nitrogen for metabolic processes. Electrolytes maintain acid-base balance and osmotic pressure.
Amino acids serve as substrates for protein synthesis and intermediary metabolism; dextrose provides caloric replacement; electrolytes maintain acid-base and electrolyte balance.
1 to 1.5 g amino acids/kg/day intravenously, typically infused over 12-24 hours.
Intravenous infusion; typical adult dose is 500 mL to 1000 mL per day administered as a continuous or intermittent infusion, providing 4.25% amino acids and 5% dextrose. Rate adjusted based on metabolic needs and tolerance.
None Documented
None Documented
Variable; amino acids typically have half-lives of minutes to hours; free amino acids in plasma have t1/2 of 10-30 minutes for most
Not applicable as a composite; amino acids have varying half-lives (minutes). Dextrose: glucose half-life ~1.5-2.5 hours in healthy individuals. Clinical context: continuous infusion maintains steady state.
Renal >90% (as amino acids and metabolites); fecal <5%
Amino acids: renal elimination of unmodified amino acids is minimal (<5%); most nitrogen is excreted as urea via kidneys. Dextrose: fully metabolized, negligible renal excretion of intact glucose. Electrolytes: renally excreted.
Category C
Category C
Amino Acid Solution
Amino Acid Solution